Novartis’ canakinumab failed to improve survival in COVID-19 study
Swiss pharma company had been studying drug in hospitalised COVID-19 patients
Novartis’ arthritis drug canakinumab failed to hit its primary endpoint of improving survival for COVID-19 patients without the need for invasive mechanical ventilation, the Swiss pharma company announced today.
Novartis had been studying the drug in hospitalised patients with COVID-19 pneumonia and cytokine release syndrome (CRS).
The trial failed to show that treatment with canakinumab plus standard of care demonstrated a significantly greater chance of survival for patients without the need for invasive mechanical ventilation, compared with standard of care at day 29.
New global partnership launched to fight future pandemics
Format
The Government will launch a new Pandemic Preparedness Partnership (PPP) to save lives from future diseases and prevent another global pandemic.
International Pandemic Preparedness Partnership (PPP) will support PM’s target to slash the time to develop vaccines for new diseases to 100 days
Partnership will be chaired by UK Chief Scientific Adviser Sir Patrick Vallance and will report to leaders at June’s G7 Summit
New £16m funding to Coalition for Epidemic Preparedness Innovations (CEPI) will also support global vaccine supply and development
The Government will today (20 April) launch a new Pandemic Preparedness Partnership (PPP) to save lives from future diseases and prevent another global pandemic.
New global partnership launched to fight future pandemics
The Government will launch a new Pandemic Preparedness Partnership (PPP) to save lives from future diseases and prevent another global pandemic.
From:
20 April 2021
International Pandemic Preparedness Partnership (PPP) will support PM’s target to slash the time to develop vaccines for new diseases to 100 days
Partnership will be chaired by UK Chief Scientific Adviser Sir Patrick Vallance and will report to leaders at June’s G7 Summit
New £16m funding to Coalition for Epidemic Preparedness Innovations (CEPI) will also support global vaccine supply and development
The Government will today (20 April) launch a new Pandemic Preparedness Partnership (PPP) to save lives from future diseases and prevent another global pandemic.
New global partnership launched to fight future pandemics
Format
The Government will launch a new Pandemic Preparedness Partnership (PPP) to save lives from future diseases and prevent another global pandemic.
International Pandemic Preparedness Partnership (PPP) will support PM’s target to slash the time to develop vaccines for new diseases to 100 days
Partnership will be chaired by UK Chief Scientific Adviser Sir Patrick Vallance and will report to leaders at June’s G7 Summit
New £16m funding to Coalition for Epidemic Preparedness Innovations (CEPI) will also support global vaccine supply and development
The Government will today (20 April) launch a new Pandemic Preparedness Partnership (PPP) to save lives from future diseases and prevent another global pandemic.